Menu
Search
|

Menu

Close
X

Myriad Genetics Inc MYGN.OQ (NASDAQ Stock Exchange Global Select Market)

43.71 USD
-0.04 (-0.09%)
As of Jul 21
chart
Previous Close 43.75
Open 43.80
Volume 123,610
3m Avg Volume 279,390
Today’s High 43.90
Today’s Low 43.25
52 Week High 44.31
52 Week Low 23.34
Shares Outstanding (mil) 68.44
Market Capitalization (mil) 2,541.79
Forward P/E 118.25
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.69 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY18
578
FY17
771
FY16
754
FY15
723
EPS (USD)
FY18
1.303
FY17
0.314
FY16
1.875
FY15
1.077
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
118.25
32.76
Price to Sales (TTM)
vs sector
3.30
5.73
Price to Book (MRQ)
vs sector
3.26
5.47
Price to Cash Flow (TTM)
vs sector
36.36
23.29
Total Debt to Equity (MRQ)
vs sector
12.73
16.84
LT Debt to Equity (MRQ)
vs sector
12.73
12.51
Return on Investment (TTM)
vs sector
2.38
14.61
Return on Equity (TTM)
vs sector
2.84
16.34

EXECUTIVE LEADERSHIP

John Henderson
Independent Chairman of the Board, Since 2005
Salary: --
Bonus: --
Mark Capone
President, Chief Executive Officer, Director, Since 2015
Salary: $852,000.00
Bonus: $307.00
Mark Verratti
President-President Assurex Health, Since 2017
Salary: --
Bonus: --
Walter Gilbert
Independent Vice Chairman of the Board, Since
Salary: --
Bonus: --
R. Bryan Riggsbee
Chief Financial Officer, Treasurer, Since 2014
Salary: $432,000.00
Bonus: $307.00

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

320 S Wakara Way
SALT LAKE CITY   UT   84108-1214

Phone: +1801.5843600

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

SPONSORED STORIES